These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 8927346

  • 1. [Cyclosporin-A therapy in autoimmune diseases].
    Patakfalvi A.
    Orv Hetil; 1996 Sep 01; 137(35):1921-7. PubMed ID: 8927346
    [Abstract] [Full Text] [Related]

  • 2. [Cyclosporin in autoimmune diseases].
    Follath F, Fontana A, Leumann E, Michel BA, Miescher PA, Schreier M, Schroeder M, Wenk M.
    Schweiz Med Wochenschr; 1994 Jul 12; 124(27-28):1232-9. PubMed ID: 8052828
    [Abstract] [Full Text] [Related]

  • 3. [Problems associated with the use and monitoring of cyclosporin. Experience at a Clinical Pharmacology Service].
    Loffreda A, Contaldi C, Santis DD, Marabese I, Chiaiese C, Formato P, Motola G, Russo F, D'Alessio O, Lampa E, Rossi F.
    Minerva Med; 1997 Dec 12; 88(12):543-9. PubMed ID: 9540786
    [Abstract] [Full Text] [Related]

  • 4. [Cyclosporin in autoimmune diseases].
    Frey FJ.
    Schweiz Med Wochenschr; 1990 May 26; 120(21):772-86. PubMed ID: 2190313
    [Abstract] [Full Text] [Related]

  • 5. [Amniotic membrane transplantation and high-dose systemic cyclosporin A (Sandimmun optoral) for Mooren's ulcer].
    Spelsberg H, Sundmacher R.
    Klin Monbl Augenheilkd; 2007 Feb 26; 224(2):135-9. PubMed ID: 17309011
    [Abstract] [Full Text] [Related]

  • 6. [Cyclosporin].
    Nojima Y.
    Nihon Rinsho; 2005 May 26; 63 Suppl 5():669-72. PubMed ID: 15954427
    [No Abstract] [Full Text] [Related]

  • 7. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?
    Manna R, Verrecchia E, Fonnesu C, Giovinale M, De Socio G, Curigliano V, Cerquaglia C, Soriano A, Granata M, Migliore A, Massafra U, Gasbarrini G.
    Eur Rev Med Pharmacol Sci; 2009 Mar 26; 13 Suppl 1():63-9. PubMed ID: 19530514
    [Abstract] [Full Text] [Related]

  • 8. Treatment of autoimmune urticaria with low-dose cyclosporin A: A one-year follow-up.
    Boubouka CD, Charissi C, Kouimintzis D, Kalogeromitros D, Stavropoulos PG, Katsarou A.
    Acta Derm Venereol; 2011 Jan 26; 91(1):50-4. PubMed ID: 21264453
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M, Pelletier GB, Tan A, Jesina C, Carrier M.
    J Heart Lung Transplant; 1997 Aug 26; 16(8):787-94. PubMed ID: 9286770
    [Abstract] [Full Text] [Related]

  • 10. [Headache associated with cyclosporin ina patient with membranous glomerulonephritis].
    Borrás Blasco J, Enríquez R, Amorós Amorós F, Navarro Ruiz A, Conesa García V, González Delgado M.
    Farm Hosp; 2004 Aug 26; 28(6):454-7. PubMed ID: 15628949
    [Abstract] [Full Text] [Related]

  • 11. Optimizing the use of cyclosporin in allogeneic stem cell transplantation.
    Duncan N, Craddock C.
    Bone Marrow Transplant; 2006 Aug 26; 38(3):169-74. PubMed ID: 16751787
    [Abstract] [Full Text] [Related]

  • 12. [Cyclosporin in treatment of glomerular diseases].
    Krieter DH, Müller GA.
    Internist (Berl); 1996 Jan 26; 37(1):84-8. PubMed ID: 8837833
    [No Abstract] [Full Text] [Related]

  • 13. Cardiovascular effects of cyclosporin treatment in an experimental model.
    Tavares P, Reis F, Ribeiro CA, Teixeira F.
    Rev Port Cardiol; 2002 Feb 26; 21(2):141-55. PubMed ID: 11963284
    [Abstract] [Full Text] [Related]

  • 14. [Cyclosporin A in inflammatory rheumatic diseases].
    Gross WL, Rob PM.
    Internist (Berl); 1996 Jan 26; 37(1):91-7. PubMed ID: 8837835
    [No Abstract] [Full Text] [Related]

  • 15. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
    Dejica D.
    Roum Arch Microbiol Immunol; 2001 Jan 26; 60(3):183-201. PubMed ID: 12165973
    [Abstract] [Full Text] [Related]

  • 16. [The combination of cyclosporin A and fluocortolone in the treatment of autoimmune diseases].
    Aresu G, Pascalis L, Pia G.
    Clin Ter; 1989 Oct 15; 131(1):3-21. PubMed ID: 2531058
    [Abstract] [Full Text] [Related]

  • 17. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
    Atakan N, Erdem C.
    J Eur Acad Dermatol Venereol; 1998 Nov 15; 11(3):240-6. PubMed ID: 9883436
    [Abstract] [Full Text] [Related]

  • 18. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.
    Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD.
    Ann N Y Acad Sci; 2007 Sep 15; 1110():544-9. PubMed ID: 17911470
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.
    Cantarovich M, Besner JG, Fitchett DH, Latter DA.
    Clin Transplant; 1997 Oct 15; 11(5 Pt 1):399-405. PubMed ID: 9361930
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of action of cyclosporin A and rationale for use in nephrotic syndrome.
    Borel JF.
    Clin Nephrol; 1991 Oct 15; 35 Suppl 1():S23-30. PubMed ID: 1860262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.